Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).

Shun LuXiaorong DongHong JianJianhua ChenGongyan ChenYuping SunYinghua JiZiping WangJianhua ShiJunguo LuShaoshui ChenDongqing LvGuojun ZhangChunling LiuJuan LiXinmin YuZhong LinZhuang YuZhehai WangJiuwei CuiXingxiang XuJian FangJifeng FengZhi XuRui MaJie HuNong YangXiangdong ZhouXiaohong WuChengping HuZhihong ZhangYou LuYanping HuLiyan JiangQiming WangRenhua GuoJianying ZhouBaolan LiChunhong HuWancheng TongHelong ZhangLin MaYuan ChenZhijun JieYu YaoLongzhen ZhangJie WengWeidong LiJianping XiongXianwei YeJianchun DuanHaihua YangMeili SunHongying WeiJiawei WeiZheyu ZhangQiong Wu

Published in: Cancer communications (London, England) (2024)

ClinicalTrials.gov number, NCT03849768.

Keyphrases

phase iii
epidermal growth factor receptor
advanced non small cell lung cancer
open label
tyrosine kinase
clinical trial
small cell lung cancer
phase ii
electronic health record
double blind
placebo controlled
big data
cerebrospinal fluid
study protocol
randomized controlled trial
machine learning
deep learning